Computational model review predicts dual optima for combination therapy in ageing
New math model shows combining drugs could slow aging better than weight loss alone
This review of a computational model explores combination therapy with semaglutide, SGLT2 inhibitors, metformin, and rapamycin for ageing.
A new computer model reveals that fixing blood sugar and slowing aging are separate tasks, meaning some drugs might help you live longer eve…
Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
No More Bone Fear With New Diabetes Drug
This meta-analysis evaluated adjunctive SGLT2 inhibitor therapy in 6,731 patients with type 1 diabetes mellitus receiving insulin-based ther…
Many people with type 1 diabetes worry about their bones.
Meta-analysis of 13 trials finds SGLT2 inhibitors reduce heart failure hospitalization in myocardial infarction
New Drug Combo Lowers Heart Failure Risk After Heart Attack
This meta-analysis synthesizes data from 13 randomized controlled trials involving 22,238 patients with myocardial infarction.
Adding a specific diabetes medication to standard heart care may prevent future heart failure after a heart attack.
Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
Semaglutide Does Not Raise Suicide Risk, Study Finds
This active-comparator, new-user target trial emulation review synthesizes data from 102,361 U.S.
A large new study finds that semaglutide does not increase suicide risk compared to other diabetes drugs, easing fears for millions of patie…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
Bayesian network meta-analysis evaluates antidiabetic medications and dementia risk in 4,382,897 patients
Could diabetes drugs lower dementia risk, or raise it for some patients?
This Bayesian network meta-analysis synthesized data from 28 articles involving 4,382,897 patients to assess antidiabetic drugs and dementia…
Insulin and metformin cut dementia risk, but DPP4 inhibitors may double Alzheimer's risk compared to SGLT2 drugs in diabetes patients.
SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
Taking More Heart Pills May Actually Feel Better, Not Worse
A cross-sectional study of 78 heart failure patients in a Malaysian MTAC program found SGLT2i users had significantly lower adherence (p = 0…
Heart failure patients taking more heart medicines reported feeling better, not worse, in a new study from Malaysia.
Meta-analysis identifies risk factors for diabetic kidney disease in Asian patients with type 2 diabetes
High Blood Pressure Is A Major Kidney Killer For Asian Diabetics
A meta-analysis of 24 studies including 12,047 Asian patients with type 2 diabetes found that SBP, hypertension, HbA1c, WHR, FBG, UA, Cr, ag…
High blood pressure is a top kidney killer for Asian diabetics, making blood pressure control just as critical as managing sugar levels to p…
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care
A Simple Chatbot After Heart Failure Hospitalization May Keep You Healthier and Out of the Hospital
This randomized controlled trial enrolled 66 patients with heart failure with reduced ejection fraction (HFrEF) recently discharged from the…
For people with heart failure, consistent digital check-ins after leaving the hospital could be the key to getting the right medication stre…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new pill for type 2 diabetes that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.